Table 1 Baseline characteristics of participants
Characteristics | MSCs group (N = 15) | Placebo group (N = 15) |
|---|---|---|
Age (years) | 67.27 ± 5.23 | 69.27 ± 5.02 |
Sex (n, %) | ||
 Male | 5 (33.33) | 7 (46.67) |
 Female | 10 (66.67) | 8 (53.33) |
BMI (kg/m2) | 24.03 ± 2.89 | 24.95 ± 3.67 |
Fried frailty phenotype scale | 2 (2, 2) | 2 (2, 3) |
Chronic conditions | ||
 Hypertension (%) | 4 (26.67) | 7 (46.67) |
 Dyslipidemia (%) | 4 (46.67) | 1 (6.67) |
 Type 2 diabetes mellitus (%) | 3 (20) | 5 (33.33) |
 Ischemic cardiomyopathy (%) | 2 (13.33) | 2 (13.33) |
Medication | ||
 Aspirin (%) | 2 (13.33) | 1 (6.67) |
 ACEI/ARB (%) | 2 (13.33) | 4 (26.67) |
 Calcium antagonists (%) | 2 (13.33) | 1 (6.67) |
 Metformin (%) | 1 (6.67) | 2 (13.33) |
 Other oral antidiabetics (%) | 2 (13.33) | 3 (20) |
 Insulin (%) | 2 (13.33) | 2 (13.33) |
 Stain (%) | 5 (33.33) | 1 (6.67) |
Laboratory | ||
 Hemoglobin (g/L) | 135.80 ± 7.72 | 132.47 ± 13.71 |
 White blood cell count (109/L) | 5.89 ± 1.37 | 5.69 ± 1.45 |
 Platelet count (109/L) | 203.2 ± 42.75 | 206.4 ± 73.50 |
 AST (U/L) | 23.07 ± 14.26 | 23.73 ± 8.68 |
 ALT (U/L) | 22.73 ± 18.18 | 21.00 ± 12.62 |
 GFR (mL/min per 1.73 m2) | 70.73 ± 13.98 | 75.93 ± 16.35 |
 FBG (mmol/L) | 5.94 ± 1.41 | 5.89 ± 1.26 |